Panitumumab submitted in competitive Japan market
This article was originally published in Scrip
Executive Summary
Takedahas filed for the Japanese approval of panitumumab, although the EGFR-targeting monoclonal antibody will face stiff competition in its lead target indication of metastatic colorectal cancer should it be approved and reach the market.
You may also be interested in...
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
PMDA Eyes More Japan-First Approvals In Access Push
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Need a specific report? 1000+ reports available
Buy Reports